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Abstract 
Review on del(21)(q21q22) USP16/RUNX1, with 
data on clinics, and the genes implicated. 
Identity 
Note 
Microdeletions and inversion at 21q21 leading to 
USP16-RUNX1 fusion in CMML. 




Male patient 74 year-old. 
Phenotype/cell stem origin 
CD4, 11b, 13, 14, 15, 33, 36, 56, 117 positive. 
Etiology 
Thrombocytopenia 2 years before, chronic 
myelomonocytic leukemia (CMML) 1 year before. 
Epidemiology 
Toxic exposure at work (oil by-products). 
Clinics 
Bilateral inguinal ADP.  
No hepatosplenomegaly. 
 No involvement of central nervous system. 
Tricytopenia: WBC 2.9x109/L, Hb 10.7g/dl and 
platelets 12x109/L. 
Cytology 
Hypercellular bone marrow, rare megakaryocytes.  
72% blast cells.  
AML-M4 with no morphologic arguments for a 
secondary leukemia. 
Treatment 
Induction Idarubicin/Aracytin. GFM Azacytidin 
protocol. 
Evolution 
Survival 2.5 years. 
Cytogenetics 
Note 
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Figure 1A: Genomic rearrangement involving USP16 and RUNX1 genes in a CMML. Profile of chromosome 21 shows regional 
deletions in 21q21.3 and 21q22.12. Arrowheads point to USP16 and RUNX1 genes targeted by transition profiles located in 
these respective regions. Figure 1B: USP16-RUNX1 rearrangement. Inversion of the 21q21.3-q22.12 region and generation of 
USP16-RUNX1 gene fusion. Organization of chromosomal region 21q21.3-q22.12 with the location of the breakpoints (BP) and 
deleted regions. The potential gene breakages and deleted regions were refined to an interval (vertical arrows and grey boxes, 
respectively) defined by aCGH. Breakpoints BP1 and BP3 targeting USP16 and RUNX1 are associated with deletions defined by 
intervals [BP1-BP2] and [BP3-BP4]. The USP16-RUNX1 gene fusion characterized by RT-PCR is explained by the inversion of 
the central interval [BP2-BP3]. ATG codons are in exon 2 (ex 2) and exon 1 (ex 1) of USP16 and RUNX1, respectively. The 
event fuses exon 1 of USP16 to exon 5 of RUNX1 not preserving the canonical ATG. 
 
 




The aCGH profile (244K CGH Microarrays Hu-
244A, Agilent Technologies, Massy, France) 
showed two losses at 21q21.3 and q22.12 of about 
1.04 Mb and 0.82 Mb, respectively (Figure 1A). 
They spanned the 3' part of USP16, including exons 
2 to 19, and the 5' part of RUNX1 (including exons 
1 to 4), respectively. 
Description 
A cryptic inv(21)(q21q22) associated with a 
microdeletion at one of the breakpoints, and a 
fusion involving RUNX1 and USP16 (encoding a 
de-ubiquitinating enzyme).  
This was confirmed by nested PCR amplification of 
reverse-transcribed RNA from the patient's BM 
cells, which detected a 245 bp-long USP16-
RUNX1 transcript.  
No reciprocal transcript was detected. Sequence 
analysis showed that the result of the 
inversion/fusion generated a chimeric USP16-
RUNX1 transcript. 
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Transcript 
The USP16-RUNX1 fusion transcript did not have 
an open reading frame using the canonical start 
codons of USP16 or RUNX1.  
However, multiple ATG codons through exons 5 to 
7 of the fused RUNX1 sequence could be used as 
new start codons and generate truncated RUNX1 
proteins. 
The break/fusion was not present in the germline 
since we did not find the USP16-RUNX1 transcript 
in buccal smear cells of the patient. 
Detection 
The 21q inversion was not detectable by 
karyotyping and would not have been detected by 




To be noted 
We found a similar USP16-RUNX1 fusion without 
microdeletion in another case of CMML, with the 
same consequences on transcript and putative 
proteins.  
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